CAR-NK cell therapy for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new type of immune cell therapy called CAR-NK cells that target two proteins (MSLN and MUC1) often found on pancreatic cancer cells. It is for people whose cancer has spread or cannot be removed, and who have already tried at least one standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with pancreatic ductal adenocarcinoma that cannot be removed by surgery or has spread to other parts of the body.
- Your cancer has gotten worse after at least one prior standard treatment, or you cannot tolerate standard therapy.
- A sample of your tumor shows it has the proteins MSLN and/or MUC1 (this will be checked by a special lab test).
- You are in good enough health to be active and care for yourself (ECOG 0 or 1) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests specially engineered immune cells (CAR-NK cells) designed to find and attack pancreatic cancer cells. The cells target specific proteins on cancer cells and may help people whose cancer has progressed despite prior treatment.
This trial tests a personalized cell therapy (CAR-NK) using donor immune cells that are engineered to find and attack one or two markers on advanced solid tumors. It may be an option for people whose tumors have these specific markers and have exhausted other treatments.
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets two markers on breast cancer cells. It is for people with advanced HER2-positive or triple-negative breast cancer who have tried other treatments and need new options.
This trial tests whether specially engineered NK cells can find and attack your type of cancer. It is for people with advanced solid tumors that haven't responded to standard treatments.
This trial tests a new type of cell therapy (CAR-NK cells) designed to attack gastric and esophageal junction cancers that have specific markers on their surface. The cells are engineered to recognize two targets on your cancer cells, which may help your immune system fight the cancer more effectively.
This trial tests a new treatment using modified natural killer cells (CAR-NK) that target two specific proteins found on your cancer cells. It is for people with advanced colorectal cancer who have tried standard treatments without success.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.